TY - JOUR
AU - Dupont, Liane
AU - Snell, Luke B
AU - Graham, Carl
AU - Seow, Jeffrey
AU - Merrick, Blair
AU - Lechmere, Thomas
AU - Maguire, Thomas J A
AU - Hallett, Sadie R
AU - Pickering, Suzanne
AU - Charalampous, Themoula
AU - Alcolea-Medina, Adela
AU - Huettner, Isabella
AU - Jimenez-Guardeño, Jose M.
AU - Acors, Sam
AU - Almeida, Nathalia
AU - Cox, Daniel
AU - Dickenson, Ruth E
AU - Galao, Rui Pedro
AU - Kouphou, Neophytos
AU - Lista, Maria Jose
AU - Ortega-Prieto, Ana Maria
AU - Wilson, Harry
AU - Winstone, Helena
AU - Fairhead, Cassandra
AU - Su, Jia Zhe
AU - Nebbia, Gaia
AU - Batra, Rahul
AU - Neil, Stuart J.D.
AU - Shankar-Hari, Manu
AU - Edgeworth, Jonathan D.
AU - Malim, Michael H.
AU - Doores, Katie J.
PY - 2021
DA - October
TI - Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern
JO - Nature Microbiology
EP - 1442
VL - 6
IS - 11
DO - https://doi.org/10.1038/s41564-021-00974-0
AB - COVID-19 vaccine design and vaccination rollout need to take into account a detailed understanding of antibody durability and cross-neutralizing potential against SARS-CoV-2 and emerging variants of concern (VOCs). Analyses of convalescent sera provide unique insights into antibody longevity and cross-neutralizing activity induced by variant spike proteins, which are putative vaccine candidates. Using sera from 38 individuals infected in wave 1, we show that cross-neutralizing activity can be detected up to 305 days pos onset of symptoms, although sera were less potent against B.1.1.7 (Alpha) and B1.351 (Beta). Over time, despite a reduction in overall neutralization activity, differences in sera neutralization potency against SARS-CoV-2 and the Alpha and Beta variants decreased, which suggests that continued antibody maturation improves tolerance to spike mutations. We also compared the cross-neutralizing activity of wave 1 sera with sera from individuals infected with the Alpha, the Beta or the B.1.617.2 (Delta) variants up to 79 days post onset of symptoms. While these sera neutralize the infecting VOC and parental virus to similar levels, cross-neutralization of different SARS-CoV-2 VOC lineages is reduced. These findings will inform the optimization of vaccines to protect against SARS-CoV-2 variants.
PB - Springer Nature
UR - https://www.research.ed.ac.uk/en/publications/0a47e1c6-055c-4298-b5d0-c4d40ff0f3e2
KW - Coronavirus (COVID-19)
KW - Immunisation and screening
ER